Litcius/Paper detail

Outpatient Fluoroquinolone Prescription Fills in the United States, 2014 to 2020: Assessing the Impact of Food and Drug Administration Safety Warnings

Deanna J. Buehrle, Marilyn M. Wagener, Cornelius J. Clancy

2021Antimicrobial Agents and Chemotherapy47 citationsDOIOpen Access PDF

Abstract

0.04) significantly increased during the study. U.S. outpatient fluoroquinolone prescription fills significantly decreased from August 2014 to February 2020, most strongly in association with May 2016 FDA warnings. FDA safety warnings are useful tools for leveraging outpatient antimicrobial stewardship.

Topics & Concepts

MoxifloxacinMedicineLevofloxacinMedical prescriptionFood and drug administrationCiprofloxacinEmergency medicineInternal medicineEnvironmental healthPharmacologyAntibioticsBiologyMicrobiologyAntibiotic Use and ResistanceAntimicrobial Resistance in StaphylococcusAntibiotics Pharmacokinetics and Efficacy
Outpatient Fluoroquinolone Prescription Fills in the United States, 2014 to 2020: Assessing the Impact of Food and Drug Administration Safety Warnings | Litcius